Pretreatment data is highly predictive of liver chemistry signals in clinical trials

Article English OPEN
Cai, Zhaohui; Bresell, Anders; Steinberg, Mark H; Silberg, Debra G; Furlong, Stephen T; (2012)
  • Publisher: Dove Medical Press
  • Journal: Drug Design, Development and Therapy,volume 6,pages359-369 (issn: 1177-8881, eissn: 1177-8881)
  • Related identifiers: pmc: PMC3513908, doi: 10.2147/DDDT.S34271
  • Subject: RM1-950 | Hy’s Law | Therapeutics. Pharmacology | GGT | bilirubin | ALT | prediction | Drug Design, Development and Therapy | Original Research | baseline

Zhaohui Cai,1,* Anders Bresell,2,* Mark H Steinberg,1 Debra G Silberg,1 Stephen T Furlong11AstraZeneca Pharmaceuticals, Wilmington, DE, USA; 2AstraZeneca Pharmaceuticals, Södertälje, Sweden*These authors contributed equally to this workPurpose: The goa... View more
  • References (16)
    16 references, page 1 of 2

    1. Food and Drug Administration. Guidance for Industry. Drug-Induced Liver Injury: Premarketing clinical evaluation.Available from: http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM174090.pdf. Accessed November 9, 2012.

    2. Temple R. Hy's law. Predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):241-243.

    3. Reuben A. Landmarks in hepatology. Hepatology. 2004;40:1478-1482.

    4. Cai Z, Christianson AM, Ståhle L, Keisu M. Reexamining transaminase elevation in Phase I clinical trials: the importance of baseline and change from baseline. Eur J Clin Pharmacol. 2009;65:1025-1035.

    5. Clinical Data Interchange Standards Consortium. CDISC Study Data Tabulation Model. SDTM Implementation Guide V3.1.1. Available from: http://www.cdisc.org/models/sdtm/v1.1/index.html. Accessed February 12, 2009.

    6. Breiman L. Random forests. Mach Learning. 2001;45:5-32.

    7. Weil JG, Bains C, Linke A, Clark DW, Stirnadel HA, Hunt CM. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. Regul Toxicol Pharmacol. 2008;52:85-88.

    8. Xu Y, Bi YF, Xu M, et al. Cross-sectional and longitudinal association of serum alanine aminotransaminase and γ-glutamyltransferase with metabolic syndrome in middle-aged and elderly Chinese people. J Diabetes. 2011;3:38-47.

    9. George J, Denney-Wilson E, Okely AD, Hardy LL, Aitken R. The population distributions, upper normal limits and correlations between liver tests among Australian adolescents. J Pediatr Child Health. 2008;44:579-585.

    10. Critical Path Institute. Predictive Safety Testing Consortium. Available from: http://www.c-path.org/pstc.cfm. Accessed February 27, 2011.

  • Metrics
    No metrics available
Share - Bookmark